<DOC>
	<DOCNO>NCT00986362</DOCNO>
	<brief_summary>To evaluate safety preliminary efficacy intravitreal microplasmin adjunct conventional vitrectomy treatment pediatric patient .</brief_summary>
	<brief_title>Clinical Trial Intravitreal Microplasmin Infants Children Scheduled Vitrectomy</brief_title>
	<detailed_description />
	<mesh_term>Plasminogen</mesh_term>
	<criteria>1 . Male female infant child 16 year age younger 2 . Patient must suitable candidate conventional 2port 3port par plana vitrectomy 3 . Patient attach vitreous somewhere posterior pole 4 . Patient 's parent guardian must willing able comply followup requirement 5 . Patient 's parent ( ) must sign informed parental permission form case schoolage child patient must sign assent form 1 . Patient diagnose Stage 1 , 2 , 3 5 retinopathy prematurity ( ROP ) time surgery 2 . Unclear medium , precludes assessment posterior pole cataract vitreal opacity 3 . Active parental/guardian drug alcohol use dependence , opinion site Investigator , would interfere parent 's guardian 's adherence study requirement 4 . Medical problem make consistent followup treatment period uncertain . 5 . Patient must participate investigational drug device study prior 30 day 6 . Female Patients childbearing potential must pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Safety pediatrics</keyword>
</DOC>